Bris­tol My­ers dusts off an old Cel­gene chemother­a­py for use in chil­dren with a rare blood can­cer

Bris­tol My­ers Squibb is bring­ing new life to a chemother­a­py drug from the old Cel­gene pipeline as it touts an­oth­er ap­proval in a rare form of blood can­cer af­fect­ing young chil­dren.

The FDA on Fri­day ap­proved Vi­daza (chem­i­cal­ly known as azac­i­ti­dine) for pe­di­atric pa­tients 1 month and old­er with new­ly di­ag­nosed ju­ve­nile myelomono­cyt­ic leukemia (JMML). The new in­di­ca­tion marks the first ap­proval for Vi­daza in more than a decade, though it’s com­mon­ly used to treat acute myeloid leukemia and myelodys­plas­tic syn­dromes (MDS).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.